BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 30850685)

  • 1. Induction of tumor-specific CTL responses using the C-terminal fragment of Viral protein R as cell penetrating peptide.
    Gross DA; Leborgne C; Chappert P; Masurier C; Leboeuf M; Monteilhet V; Boutin S; Lemonnier FA; Davoust J; Kichler A
    Sci Rep; 2019 Mar; 9(1):3937. PubMed ID: 30850685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.
    André F; Chaput N; Schartz NE; Flament C; Aubert N; Bernard J; Lemonnier F; Raposo G; Escudier B; Hsu DH; Tursz T; Amigorena S; Angevin E; Zitvogel L
    J Immunol; 2004 Feb; 172(4):2126-36. PubMed ID: 14764678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of HLA class I tetramers to design a vaccination strategy for melanoma patients.
    Palmowski M; Salio M; Dunbar RP; Cerundolo V
    Immunol Rev; 2002 Oct; 188():155-63. PubMed ID: 12445289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human immunodeficiency virus type 1 Nef epitopes recognized in HLA-A2 transgenic mice in response to DNA and peptide immunization.
    Sandberg JK; Leandersson AC; Devito C; Kohleisen B; Erfle V; Achour A; Levi M; Schwartz S; Kärre K; Wahren B; Hinkula J
    Virology; 2000 Jul; 273(1):112-9. PubMed ID: 10891413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice.
    Vertuani S; Triulzi C; Roos AK; Charo J; Norell H; Lemonnier F; Pisa P; Seliger B; Kiessling R
    Cancer Immunol Immunother; 2009 May; 58(5):653-64. PubMed ID: 18820911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a novel HLA-A2-restricted cytotoxic T lymphocyte epitope from cancer-testis antigen PLAC1 in breast cancer.
    Liu W; Zhai M; Wu Z; Qi Y; Wu Y; Dai C; Sun M; Li L; Gao Y
    Amino Acids; 2012 Jun; 42(6):2257-65. PubMed ID: 21710262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Derivation of HLA-B*0702 transgenic mice: functional CTL repertoire and recognition of human B*0702-restricted CTL epitopes.
    Alexander J; Oseroff C; Sidney J; Sette A
    Hum Immunol; 2003 Feb; 64(2):211-23. PubMed ID: 12559623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of major epitopes of Mycobacterium tuberculosis AG85B that are recognized by HLA-A*0201-restricted CD8+ T cells in HLA-transgenic mice and humans.
    Geluk A; van Meijgaarden KE; Franken KL; Drijfhout JW; D'Souza S; Necker A; Huygen K; Ottenhoff TH
    J Immunol; 2000 Dec; 165(11):6463-71. PubMed ID: 11086086
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Schmidt J; Guillaume P; Dojcinovic D; Karbach J; Coukos G; Luescher I
    J Biol Chem; 2017 Jul; 292(28):11840-11849. PubMed ID: 28536262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel breast-tumor-associated MUC1-derived peptides: characterization in Db-/- x beta2 microglobulin (beta2m) null mice transgenic for a chimeric HLA-A2.1/Db-beta2 microglobulin single chain.
    Carmon L; El-Shami KM; Paz A; Pascolo S; Tzehoval E; Tirosh B; Koren R; Feldman M; Fridkin M; Lemonnier FA; Eisenbach L
    Int J Cancer; 2000 Feb; 85(3):391-7. PubMed ID: 10652432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel HLA-A2-restricted CTL epitope of tumor-associated antigen L6 can inhibit tumor growth in vivo.
    Tu SH; Huang HI; Lin SI; Liu HY; Sher YP; Chiang SK; Chong P; Roffler S; Tseng GC; Chen HW; Liu SJ
    J Immunother; 2012 Apr; 35(3):235-44. PubMed ID: 22421941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses.
    Lu J; Higashimoto Y; Appella E; Celis E
    J Immunol; 2004 Apr; 172(7):4575-82. PubMed ID: 15034075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein.
    Butterfield LH; Meng WS; Koh A; Vollmer CM; Ribas A; Dissette VB; Faull K; Glaspy JA; McBride WH; Economou JS
    J Immunol; 2001 Apr; 166(8):5300-8. PubMed ID: 11290817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An HLA-A2 polyepitope vaccine for melanoma immunotherapy.
    Mateo L; Gardner J; Chen Q; Schmidt C; Down M; Elliott SL; Pye SJ; Firat H; Lemonnier FA; Cebon J; Suhrbier A
    J Immunol; 1999 Oct; 163(7):4058-63. PubMed ID: 10491010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracellular delivery of a novel multiepitope peptide vaccine by an amphipathic peptide carrier enhances cytotoxic T-cell responses in HLA-A*201 mice.
    Dakappagari NK; Sundaram R; Rawale S; Liner A; Galloway DR; Kaumaya PT
    J Pept Res; 2005 Feb; 65(2):189-99. PubMed ID: 15705163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA fusion vaccines induce epitope-specific cytotoxic CD8(+) T cells against human leukemia-associated minor histocompatibility antigens.
    Rice J; Dunn S; Piper K; Buchan SL; Moss PA; Stevenson FK
    Cancer Res; 2006 May; 66(10):5436-42. PubMed ID: 16707472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral vaccination with attenuated Salmonella enterica strains encoding T-cell epitopes from tumor antigen NY-ESO-1 induces specific cytotoxic T-lymphocyte responses.
    Meng JZ; Dong YJ; Huang H; Li S; Zhong Y; Liu SL; Wang YD
    Clin Vaccine Immunol; 2010 Jun; 17(6):889-94. PubMed ID: 20375244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HLA-A2.1/K(b) transgenic murine dendritic cells transduced with an adenovirus encoding human gp100 process the same A2.1-restricted peptide epitopes as human antigen-presenting cells and elicit A2.1-restricted peptide-specific CTL.
    Yang S; Linette GP; Longerich S; Roberts BL; Haluska FG
    Cell Immunol; 2000 Aug; 204(1):29-37. PubMed ID: 11006015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA fusion vaccine designed to induce cytotoxic T cell responses against defined peptide motifs: implications for cancer vaccines.
    Rice J; Elliott T; Buchan S; Stevenson FK
    J Immunol; 2001 Aug; 167(3):1558-65. PubMed ID: 11466377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulation and characterization of a ten-peptide single-vial vaccine, EP-2101, designed to induce cytotoxic T-lymphocyte responses for cancer immunotherapy.
    Beebe M; Qin M; Moi M; Wu S; Heiati H; Walker L; Newman M; Fikes J; Ishioka GY
    Hum Vaccin; 2008; 4(3):210-8. PubMed ID: 18382135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.